Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex System) in Patients With Ataxia Telangiectasia Who Participated in the ATTeST-IEDAT-02-2015 Study

NCT03563053 is registered in ClinicalTrials.gov with Quince Therapeutics S.p.A. as lead sponsor.

NCT NCT03563053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03563053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex System) in Patients With Ataxia Telangiectasia Who Participated in the ATTeST-IEDAT-02-2015 Study
Lead sponsor
Quince Therapeutics S.p.A.
Phase
Phase 3
Overall status
Terminated
Start date
June 12, 2018
Completion date
September 2, 2022
Enrollment
104 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ataxia telangiectasia, genetic syndrome